SEARCH

SEARCH BY CITATION

References

  • 1
    Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 4: 6929.
  • 2
    Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 116773.
  • 3
    World Health Organization. Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser 1998; 877: 189.
  • 4
    Jordan WM. Pulmonary embolism. Lancet 1961; 2: 11467.
  • 5
    Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case–control study. Int J Epidemiol 1992; 1: 4852.
  • 6
    Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 14537.
  • 7
    Anonymous. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case–control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraceptio. Lancet 1995; 346: 157582.
  • 8
    Anonymous. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346: 15828.
  • 9
    Farmer RDT, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997; 349: 838.
  • 10
    van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case–control study. BMJ 2009; 339: b2921.
  • 11
    Lidegaard O, Lokkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009; 339: b2890.
  • 12
    Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. BMJ (Clin Res Ed) 1986; 292: 526.
  • 13
    Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 1: 327.
  • 14
    Levi M, Middeldorp S, Buller HR. Oral contraceptives and hormonal replacement therapy cause an imbalance in coagulation and fibrinolysis which may explain the increased risk of venous thromboembolism. Cardiovasc Res 1999; 1: 214.
  • 15
    Vandenbroucke JP, Rosing J, Bloemenkamp KWM, Middeldorp S, Helmerhorst FM, Bouma BN, Rosendaal FR. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 20: 152735.
  • 16
    Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001; 323: 1314.
  • 17
    Rosing J, Tans G, Nicolaes GA, Thomassen MC, van Oerle R, van der Ploeg PM, Heijnen P, Hamulyak K, Hemker HC. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 1: 2338.
  • 18
    Rosing J, Middeldorp S, Curvers J, Thomassen MC, Nicolaes GA, Meijers JCM, Bouma BN, Buller HR, Prins MH, Tans G. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet 1999; 97: 203640.
  • 19
    Middeldorp S, Meijers JCM, van den Ende AE, van Enk A, Bouma BN, Tans G, Rosing J, Prins MH, Buller HR. Effects on coagulation of levonorgestrel and desogestrel-containing low dose oral contraceptives: a cross-over study. Thromb Haemost 2000; 1: 48.
  • 20
    Tans G, Curvers J, Middeldorp S, Thomassen MCL, Meijers JCM, Prins MH, Bouma BN, Buller HR, Rosing J. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thromb Haemost 2000; 1: 1521.
  • 21
    Meijers JCM, Middeldorp S, Tekelenburg W, van den Ende AE, Tans G, Prins MH, Rosing J, Buller HR, Bouma BN. Increased fibrinolytic activity of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis. A randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost 2000; 1: 914.
  • 22
    Parkin L, Skegg DCG, Wilson M, Herbison GP, Paul C. Oral contraceptives and fatal pulmonary embolism. Lancet 2000; 355: 21334.
  • 23
    Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358: 14279.
  • 24
    Seaman HE, Vries CS, Farmer RD. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case–control study. Hum Reprod 2003; 18: 5226.
  • 25
    van Grootheest K, Vrieling T. Thromboembolism associated with the new contraceptive Yasmin. BMJ 2003; 326: 257.
  • 26
    Pearce HM, Layton D, Wilton LV, Shakir SA. Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin. Br J Clin Pharmacol 2005; 1: 98102.
  • 27
    Mira Y, Morata C, Vaya A, Ferrando F, Contreras T, Aznar J. Is Yasmin as safe as other contraceptive pills? Clin Appl Thromb Hemost 2006; 3: 3789.
  • 28
    Lopez M, Vaya A, Martinez Triguero ML, Contreras MT, Todoli J, Ricart A, Laiz B. Yasmin and venous thromboembolism: new case reports. Clin Hemorheol Microcirc 2009; 1: 659.
  • 29
    Poulter NR, Chang CL, Farley TM, Meirik O. Risk of cardiovascular diseases associated with oral progestagen preparations with therapeutic indications. Lancet 1999; 354: 1610.
  • 30
    Vasilakis C, Jick H, Melero-Montes MD. Risk of idiopathic venous thromboembolism in users of progestagens alone. Lancet 1999; 354: 161011.
  • 31
    Anonymous. Cardiovascular disease and use of oral and injectable progestagen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case–control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Contraception 1998; 5: 31524.
  • 32
    Henkens CM, Bom VJ, Seinen AJ, van der Meer J. Sensitivity to activated protein C; influence of oral contraceptives and sex. Thromb Haemost 1995; 3: 4024.
  • 33
    Tchaikovski SN, van Vliet HA, Thomassen MC, Bertina RM, Rosendaal FR, Sandset PM, Helmerhorst FM, Tans G, Rosing J. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography. Thromb Haemost 2007; 6: 13506.
  • 34
    van Vliet HA, Bertina RM, Dahm AE, Rosendaal FR, Rosing J, Sandset PM, Helmerhorst FM. Different effects of oral contraceptives containing different progestogens on protein S and tissue factor pathway inhibitor. J Thromb Haemost 2008; 2: 34651.
  • 35
    van Hylckama Vlieg A, Helmerhorst FM, Rosendaal FR. The risk of deep venous thrombosis associated with injectable DMPA contraceptives or a Levonorgestrel intrauterine device. Arterioscler Thromb Vasc Biol 2010; 30: 2297300.
  • 36
    Goldstein J, Cushman M, Badger GJ, Johnson JV. Effect of depomedroxyprogesterone acetate on coagulation parameter: a pilot study. Fertil Steril 2007; 6: 126770.
  • 37
    Walsh JS, Eastell R, Peel NF. Effects of Depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case–control study. J Clin Endocrinol Metab 2008; 4: 131723.
  • 38
    Whigham KA, Howie PW, Mack A, Prentice CR. The effect of an injectable progestogen contraceptive on blood coagulation and fibrinolysis. Br J Obstet Gynaecol 1979; 10: 8069.
  • 39
    Fahmy K, Khairy M, Allam G, Gobran F, Alloush M. Effect of depo-medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women. Contraception 1991; 4: 43144.
  • 40
    Shulman LP, Nelson AL, Darney PD. Recent developments in hormone delivery systems. Am J Obstet Gynecol 2004; 190 (Suppl. 4): S3948.
  • 41
    Jensen JT. Contraceptive and therapeutic effects of the levonorgestrel intrauterine system: an overview. Obstet Gynecol Surv 2005; 9: 60412.
  • 42
    van Vliet HA, Tchaikovski SN, Rosendaal FR, Rosing J, Helmerhorst FM. The effect of the levonorgestrel-releasing intrauterine system on the resistance to activated protein C (APC). Thromb Haemost 2009; 4: 6915.
  • 43
    Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006; 2: 16978.
  • 44
    Jick S, Kaye JA, Li L, Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception 2007; 1: 47.
  • 45
    Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol 2007; 2 Pt 1: 33946.
  • 46
    Dore DD, Norman H, Loughlin J, Seeger JD. Extended case–control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception 2010; 5: 40813.
  • 47
    Johnson JV, Lowell J, Badger GJ, Rosing J, Tchaikovski S, Cushman M. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Obstet Gynecol 2008; 2 Pt 1: 27884.
  • 48
    Kluft C, Meijer P, LaGuardia KD, Fisher AC. Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables. Contraception 2008; 2: 7783.
  • 49
    Jensen JT, Burke AE, Barnhart KT, Tillotson C, Messerle-Forbes M, Peters D. Effects of switching from oral to transdermal or transvaginal contraception on markers of thrombosis. Contraception 2008; 6: 4518.
  • 50
    Fleischer K, van Vliet HA, Rosendaal FR, Rosing J, Tchaikovski S, Helmerhorst FM. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study. Thromb Res 2009; 3: 42935.
  • 51
    van Vliet HA, Rosendaal FR, Fleischer K, Rosing J, Helmerhorst FM. Effects of the contraceptive vaginal ring, the contraceptive transdermal patch and combined oral contraceptives on markers of hemostasis. Contraception 2010; 1: 889.
  • 52
    Lindqvist PG, Rosing J, Malmquist A, Hillarp A. Etonogestrel implant use is not related to hypercoagulable changes in anticoagulant system. J Thromb Haemost 2003; 3: 6012.
  • 53
    Vieira CS, Ferriani RA, Garcia AA, Pintao MC, Azevedo GD, Gomes MK, Silva-de-Sa MF. Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade. Hum Reprod 2007; 8: 2196201.
  • 54
    Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein(a) concentrations: analysis of studies published from 1974–2000. Fertil Steril 2001; 75: 898915.
  • 55
    Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health 1998; 19: 5572.
  • 56
    Barrett-Connor E, Wenger NK, Grady D, Mosca L, Collins P, Kornitzer M, Cox DA, Moscarelli E, Anderson PW. Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene. J Womens Health 1998; 7: 83947.
  • 57
    Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 7: 60513.
  • 58
    Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, Hsia J, Hulley S, Herd A, Khan S, Newby LK, Waters D, Vittinghoff E, Wenger N. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 1: 4957.
  • 59
    Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principle results from the Women’s Health Initiative randomized controlled trial. JAMA 2002; 3: 32133.
  • 60
    Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy. JAMA 2002; 7: 87281.
  • 61
    Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 9033: 97780.
  • 62
    Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997; 7101: 14953.
  • 63
    Barrett-Connor E, Stuenkel CA. Hormone replacement therapy (HRT) – risks and benefits. Int J Epidemiol 2001; 3: 4236.
  • 64
    Curb JD, Prentice RL, Bray PF, Langer RD, van Horn L, Barnabei VM, Bloch MJ, Cyr MG, Gass M, Lepine L, Rodabough RJ, Sidney S, Uwaifo GI, Rosendaal FR. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006; 7: 77280.
  • 65
    Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008; 336: 122731.
  • 66
    Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Weiss NS, Larson EB, Rosendaal FR, Psaty BM. Esterified estrogens and conjugated equine estrogens and the risk of venous thrombosis. JAMA 2004; 13: 15817.
  • 67
    Smith NL, Heckbert SR, Lemaitre RN, Reiner AP, Lumley T, Rosendaal FR, Psaty BM. Conjugated equine estrogen, esterified estrogen, prothrombotic variants, and the risk of venous thrombosis in postmenopausal women. Arterioscler Thromb Vasc Biol 2006; 12: 280712.
  • 68
    Perez Gutthann S, Garcia Rodriguez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism: population based case–control study. BMJ 1997; 314: 796800.
  • 69
    Douketis JD, Julian JA, Kearon C, Anderson DR, Crowther MA, Bates SM, Barone M, Piovella F, Turpie AG, Middeldorp S, van Nguyen P, Prandoni P, Wells PS, Kovacs MJ, MacGillavry MR, Constantini L, Ginsberg JS. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case–control study J Thromb Haemost 2005; 5: 9438.
  • 70
    Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 7: 8405.
  • 71
    Renoux C, Dell’aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: population-based study. J Thromb Haemost 2010; 8: 97986.
  • 72
    Canonico M, Fournier A, Carcaillon L, Olie V, Plu-Bureau G, Oger E, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F, Scarabin PY. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010; 2: 3405.
  • 73
    Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R. The effects of tibolone in older postmenopausal women. N Engl J Med 2008; 7: 697708.
  • 74
    Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol 2009; 2: 13546.
  • 75
    Eilertsen AL, Sandvik L, Mowinckel MC, Andersen TO, Qvigstad E, Sandset PM. Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis. Thromb Res 2007; 3: 3719.
  • 76
    Eilertsen AL, Liestol S, Mowinckel MC, Hemker HC, Sandset PM. Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system. Thromb Haemost 2007; 6: 93843.
  • 77
    Keramaris NC, Christodoulakos GE, Lambrinoudaki IV, Dalamanga A, Alexandrou AP, Bramis J, Bastounis E, Creatsas GC. The differential effect of estrogen, estrogen–progestin and tibolone on coagulation inhibitors in postmenopausal women. Climacteric 2007; 5: 4007.
  • 78
    Hemelaar M, van der Mooren MJ, Rad M, Kluft C, Kenemans P. Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic review. Fertil Steril 2008; 3: 64272.
  • 79
    Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 5: 9338.
  • 80
    Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 2: 15560.
  • 81
    World Health Organization. Medical Eligibility Criteria for Contraceptive Use. Geneva: World Health Organization, 2004.
  • 82
    Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Factor V Leiden – should we screen oral contraceptive users and pregnant women? BMJ 1996; 313: 112730.
  • 83
    Cohn DM, Roshani S, Middeldorp S. Thrombophilia and venous thromboembolism: implications for testing? Semin Thromb Hemost 2007; 6: 57381.
  • 84
    Lensen RPM, Rosendaal FR, Koster T, Allaart CF, Deronde H, Vandenbroucke JP, Reitsma PH, Bertina RM. Apparent different thrombotic tendency in patients with factor V Leiden and protein C deficiency due to selection of patients. Blood 1996; 11: 42058.
  • 85
    Simioni P, Sanson BJ, Prandoni P, Tormene D, Friederich PW, Girolami B, Gavasso S, Huisman MV, Buller HR, ten Cate JW, Girolami A, Prins MH. The incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 2: 198202.
  • 86
    Middeldorp S, Henkens CMA, Koopman MMW, van Pampus ECM, van der Meer J, Hamulyak K, Prins MH, Buller HR. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998; 1: 1520.
  • 87
    Middeldorp S, Meinardi JR, Koopman MMW, van Pampus ECM, Hamulyak K, van der Meer J, Prins MH, Buller HR. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001; 5: 3227.
  • 88
    Bank I, Libourel EJ, Middeldorp S, van Pampus ECM, Koopman MMW, Hamulyak K, Prins MH, van der Meer J, Buller HR Prothrombin 20210A mutation: a mild risk factor for venous thromboembolism but not for arterial thrombotic disease and pregnancy-related complications in a family study. Arch Intern Med 2004; 17: 19327.
  • 89
    Bank I, Libourel EJ, Middeldorp S, Hamulyak K, van Pampus ECM, Koopman MMW, Prins MH, van der Meer J, Buller HR. Elevated levels of FVIII:c within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 2005; 1: 7984.
  • 90
    van de Poel MH, Coppens M, Middeldorp S, Hamulyak K, Veeger NJ, Prins MH, Buller HR, van der Meer J. Absolute risk of venous and arterial thromboembolism associated with mild hyperhomocysteinemia. Results from a retrospective family cohort study. J Thromb Haemost 2005; 3: P0481.
  • 91
    Coppens M, van der Poel MH, Bank I, Hamulyak K, van der Meer J, Veeger NJ, Prins MH, Buller HR, Middeldorp S. A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. Blood 2006; 108: 26047.
  • 92
    Lijfering W, Coppens M, van der Poel MH, Middeldorp S, Hamulyak K, Bank I, Veeger NJ, Prins MH, Buller HR, van der Meer J. The risk of venous and arterial thrombosis in hyperhomocysteinemia is low and mainly depends on concomitant thrombophilic defects. Thromb Haemost 2007; 98: 45763.
  • 93
    Bank I, van de Poel MH, Coppens M, Hamulyak K, Prins MH, van der Meer J, Veeger NJ, Buller HR, Middeldorp S. Absolute annual incidences of first events of venous thromboembolism and arterial vascular events in individuals with elevated FVIII:c: a prospective family cohort study. Thromb Haemost 2007; 98: 10404.
  • 94
    Makelburg ABU, Lijfering W, Middeldorp S, Hamulyak K, Veeger NJ, Prins MH, Buller HR, van der Meer J. Low absolute risk of venous and arterial thrombosis in hyperhomocysteinaemia: a prospective family cohort study in asymptomatic subjects. Thromb Haemost 2009; 1: 20912.
  • 95
    Martinelli I. Pros and cons of thrombophilia testing: pros. J Thromb Haemost 2003; 3: 41011.
  • 96
    Machin SJ. Pros and cons of thrombophilia testing: cons. J Thromb Haemost 2003; 3: 41213.
  • 97
    Aznar J, Mira Y, Vaya A, Ferrando F, Villa P. Is family history sufficient to identify women with risk of venous thromboembolism before commencing the contraceptive pill? Clin Appl Thromb Hemost 2002; 2: 13941.
  • 98
    Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJ. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2008; 6: 61015.
  • 99
    Badaracco MA, Vessey MP. Recurrence of venous thromboembolic disease and use of oral contraceptives. BMJ 1974; 1: 21517.
  • 100
    Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 2005; 19: 235261.
  • 101
    Hutten BA, Prins MH. Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism. Cochrane Database Syst Rev 2000; 3: CD001367.
  • 102
    Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (Suppl. 6): 844S86S.
  • 103
    Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy. Results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 2000; 84: 9617.